Brinker Capital Investments, LLC Biomarin Pharmaceutical Inc Transaction History

Brinker Capital Investments, LLC

$5.01 Billion
Q4 2022

A detailed history of Brinker Capital Investments, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 19,141 shares of BMRN stock, worth $1.24 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

19,141

Previous 21,024 8.96%

Holding current value

$1.24 Million

Previous $1.78 Million 11.11%

% of portfolio

0.04%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$80.93 - $108.63 $152,391 - $204,550	-1,883 Reduced 8.96%	19,141 $1.98 Million
Q3 2022 Nov 01, 2022	BUY	$82.16 - $96.94 $4,600 - $5,428	56 Added 0.27%	21,024 $1.78 Million
Q2 2022 Jul 18, 2022	BUY	$71.48 - $86.85 $316,227 - $384,224	4,424 Added 26.74%	20,968 $1.74 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $356,321 - $444,633	4,797 Added 40.84%	16,544 $1.28 Million
Q4 2021 Feb 08, 2022	SELL	$71.72 - $91.47 $1.05 Million - $1.34 Million	-14,626 Reduced 55.46%	11,747 $1.04 Million
Q2 2021 Aug 03, 2021	BUY	$75.51 - $84.79 $341,380 - $383,335	4,521 Added 20.69%	26,373 $2.2 Million
Q1 2021 May 12, 2021	SELL	$74.73 - $90.69 $1.64 Million - $1.99 Million	-21,934 Reduced 50.09%	21,852 $1.65 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $1.82 Million - $2.26 Million	25,097 Added 134.29%	43,786 $3.84 Million
Q3 2020 Dec 03, 2020	BUY	$71.87 - $131.03 $1.34 Million - $2.45 Million	18,689 New	18,689 $1.42 Million
Q4 2019 Feb 06, 2020	SELL	$64.27 - $86.37 $4,948 - $6,650	-77 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $5,189 - $6,553	77 New	77 $5,000

Others Institutions Holding BMRN

# of Institutions

630

Shares Held

183M

Call Options Held

Put Options Held

1.72M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.

Account

Brinker Capital Investments, LLC Biomarin Pharmaceutical Inc Transaction History